From: Cellular and vaccine therapeutic approaches for gliomas
Center/Investigator | Therapy/Protocol | Phase - Enrollment | ND, P, R* | WHO Grade*** | Clinicaltrials.gov identifier | References |
---|---|---|---|---|---|---|
City of Hope, Duarte, CA/B Badie | Allogeneic T Cells modified with chimeric IL-13α2 - TCRζ | I - 10 | R, P | III or IV | NCT01082926 | Kahlon et al [9] |
Baylor College of Medicine, Houston, TX/N Ahmed | Autologous CMV specific CTL genetically modified to target Her2 | I/II - 18 | ND | IV | NCT01109095 | Ahmed et al [18] |
Penn State University, Hershey, PA/K Lucas | Allogeneic, CMV specific CTL | I/II - 10 | R | IV | NCT00990496 | |
UCLA, Los Angeles, CA/L Liau | Alloreactive CTL and IL-2 | 1 - 15 | R | III | NCT01144247 | Kruse & Rubinstein [21] |
Hoag Cancer Center, Newport Beach, CA/R Dillman | Autologous LAK Cells | II - 80 | ND | IV | NCT00814593 |